verapamil has been researched along with Aura in 44 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Faster metabolism of (R)-[(11)C]verapamil in epilepsy patients may be caused by hepatic cytochrome P450 enzyme induction by antiepileptic drugs." | 9.13 | Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. ( Abrahim, A; Bauer, M; Baumgartner, C; Joukhadar, C; Karch, R; Kletter, K; Lammertsma, AA; Langer, O; Lubberink, M; Luurtsema, G; Müller, M; Pataraia, E, 2008) |
| "Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus." | 7.80 | Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. ( Iannetti, P; Nicita, F; Nikanorova, M; Papetti, L; Parisi, P; Spalice, A, 2014) |
| " Pentylenetetrazole (PTZ)-kindled and spontaneous model of epilepsy (EL) mice were used as models of chemically induced and spontaneous epilepsy, respectively." | 7.80 | Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. ( Ohtsuki, S; Terasaki, T; Uchida, Y, 2014) |
| "The failure of the maximum tolerated dosage to improve seizure control in dogs with phenobarbital-resistant epilepsy argues against the suitability of verapamil add-on treatment to overcome pharmacoresistance." | 7.77 | Add-on treatment with verapamil in pharmacoresistant canine epilepsy. ( Jambroszyk, M; Potschka, H; Tipold, A, 2011) |
| "Verapamil was added to the antiepileptic drug regimen of a 24-year-old woman with intractable epilepsy." | 7.72 | Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. ( McAuley, JW; Moore, JL; Summers, MA, 2004) |
| "This was a single-centered, randomized, double-blind and placebo-controlled trial evaluating verapamil as an add-on therapy for adult patients with refractory epilepsy." | 5.19 | A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures. ( Ali, A; Andrade, DM; Borlot, F; Verocai, F; Wither, RG; Wu, N, 2014) |
| "Faster metabolism of (R)-[(11)C]verapamil in epilepsy patients may be caused by hepatic cytochrome P450 enzyme induction by antiepileptic drugs." | 5.13 | Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. ( Abrahim, A; Bauer, M; Baumgartner, C; Joukhadar, C; Karch, R; Kletter, K; Lammertsma, AA; Langer, O; Lubberink, M; Luurtsema, G; Müller, M; Pataraia, E, 2008) |
| "Literature searches were conducted utilizing PubMed and MEDLINE databases employing combinations of search terms including, but not limited to, "epilepsy", "refractory", "seizure", and the following medications: acetazolamide, amantadine, bumetanide, imipramine, lidocaine, verapamil, and various stimulants." | 4.95 | Outside the box: Medications worth considering when traditional antiepileptic drugs have failed. ( Perry, MS; Turner, AL, 2017) |
| "Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus." | 3.80 | Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. ( Iannetti, P; Nicita, F; Nikanorova, M; Papetti, L; Parisi, P; Spalice, A, 2014) |
| " Pentylenetetrazole (PTZ)-kindled and spontaneous model of epilepsy (EL) mice were used as models of chemically induced and spontaneous epilepsy, respectively." | 3.80 | Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. ( Ohtsuki, S; Terasaki, T; Uchida, Y, 2014) |
| "The failure of the maximum tolerated dosage to improve seizure control in dogs with phenobarbital-resistant epilepsy argues against the suitability of verapamil add-on treatment to overcome pharmacoresistance." | 3.77 | Add-on treatment with verapamil in pharmacoresistant canine epilepsy. ( Jambroszyk, M; Potschka, H; Tipold, A, 2011) |
| "Verapamil was added to the antiepileptic drug regimen of a 24-year-old woman with intractable epilepsy." | 3.72 | Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. ( McAuley, JW; Moore, JL; Summers, MA, 2004) |
| "In order to determine whether the anticonvulsant effect of 2, 3-benzodiazepines is also displayed in a model of in vitro epilepsy, such as the "epileptiform" hippocampal slice, we studied the effects of 2,3-benzodiazepine 1-(4-aminophenyl)-4-methyl-7, 8-methylenedioxe-5H 2,3-benzodiazepine hydrochloride (GYKI 52466) and some new 2,3-benzodiazepine derivatives on CA1 basal neuronal excitability and on CA1 epileptiform burst activity produced by 4-aminopyridine in rat hippocampal slices." | 3.70 | Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity. ( Gatta, F; Marinelli, S; Sagratella, S, 2000) |
| " The paper addresses this question by exploring the antiepileptic efficacy of the L-type calcium channel blockers verapamil and nifedipine in low-Mg(2+)-epilepsy in rat hippocampal slices of different postnatal (PN) ages." | 3.70 | Differential involvement of L-type calcium channels in epileptogenesis of rat hippocampal slices during ontogenesis. ( Köhling, R; Speckmann, EJ; Straub, H, 2000) |
| "The aim of the present study was to test whether the organic calcium channel blocker verapamil acts not only on spontaneously occurring epileptiform field potentials (EFP) but also on EFP triggered by single electrical stimuli in the low-Mg2+ epilepsy model." | 3.69 | Spontaneous and stimulus-triggered epileptic discharges: delayed antiepileptic effect with triggering. ( Köhling, R; Speckmann, EJ; Straub, H, 1994) |
| "Carbamazepine (CBZ) is known to have beneficial effects in the treatment of epilepsies and in the prophylaxis of affective disorders." | 3.68 | Calcium-antagonistic effects of carbamazepine in epilepsies and affective psychoses. ( Bingmann, D; Düsing, R; Grunze, H; Liu, Z; Mayer, A; Schirrmacher, K; Walden, J, 1993) |
| "Carbamazepine (CBZ) is used in neurology for the treatment of epilepsies and trigeminal neuralgia and in psychiatry for the prophylactic treatment of affective and schizoaffective psychoses." | 3.68 | Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. ( Bingmann, D; Düsing, R; Grunze, H; Liu, Z; Walden, J, 1992) |
| "Trimipramine has been classified as an atypical tricyclic antidepressant, because only weak inhibitory effects on serotonin and/or noradrenaline reuptake have been found." | 1.30 | Effects of the atypical antidepressant trimipramine on field potentials in the low Mg2+-model in guinea pig hippocampal slices. ( Berger, M; Langosch, JM; Repp, M; Walden, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.82) | 18.7374 |
| 1990's | 18 (40.91) | 18.2507 |
| 2000's | 11 (25.00) | 29.6817 |
| 2010's | 12 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Bai, YF | 1 |
| Chiu, M | 1 |
| Chan, ES | 1 |
| Axerio-Cilies, P | 1 |
| Lu, J | 1 |
| Huh, L | 1 |
| Connolly, MB | 1 |
| Guella, I | 1 |
| Farrer, MJ | 1 |
| Xu, ZD | 1 |
| Liu, L | 1 |
| Demos, M | 1 |
| Wang, YT | 1 |
| Turner, AL | 1 |
| Perry, MS | 1 |
| Nicita, F | 1 |
| Spalice, A | 1 |
| Papetti, L | 1 |
| Nikanorova, M | 1 |
| Iannetti, P | 1 |
| Parisi, P | 1 |
| Ma, A | 1 |
| Wang, C | 1 |
| Chen, Y | 1 |
| Yuan, W | 1 |
| Kumar, A | 1 |
| Tripathi, D | 1 |
| Paliwal, VK | 1 |
| Neyaz, Z | 1 |
| Agarwal, V | 1 |
| Uchida, Y | 1 |
| Ohtsuki, S | 1 |
| Terasaki, T | 1 |
| Borlot, F | 1 |
| Wither, RG | 1 |
| Ali, A | 1 |
| Wu, N | 1 |
| Verocai, F | 1 |
| Andrade, DM | 1 |
| Han, DY | 1 |
| Guan, BJ | 1 |
| Wang, YJ | 1 |
| Hatzoglou, M | 1 |
| Mu, TW | 1 |
| Bauer, M | 2 |
| Karch, R | 2 |
| Neumann, F | 1 |
| Wagner, CC | 1 |
| Kletter, K | 2 |
| Müller, M | 2 |
| Löscher, W | 2 |
| Zeitlinger, M | 1 |
| Langer, O | 2 |
| Jambroszyk, M | 1 |
| Tipold, A | 1 |
| Potschka, H | 2 |
| Kovács, R | 1 |
| Raue, C | 1 |
| Gabriel, S | 1 |
| Heinemann, U | 1 |
| Chen, L | 1 |
| Feng, P | 1 |
| Li, Y | 1 |
| Zhou, D | 1 |
| Fedrowitz, M | 1 |
| Gorji, A | 2 |
| Moddel, G | 1 |
| Speckmann, EJ | 11 |
| Summers, MA | 1 |
| Moore, JL | 1 |
| McAuley, JW | 1 |
| Rüschenschmidt, C | 1 |
| Straub, H | 8 |
| Köhling, R | 6 |
| Siep, E | 1 |
| Doyle, KM | 1 |
| Kirby, BP | 1 |
| Murphy, D | 1 |
| Shaw, GG | 1 |
| Abrahim, A | 1 |
| Luurtsema, G | 1 |
| Lubberink, M | 1 |
| Pataraia, E | 1 |
| Joukhadar, C | 1 |
| Lammertsma, AA | 1 |
| Baumgartner, C | 1 |
| Link, MC | 1 |
| Wiemann, M | 2 |
| Bingmann, D | 3 |
| Kryzhanovskiĭ, GN | 1 |
| Karpova, MN | 1 |
| Abrosimov, IIu | 1 |
| Pankov, OIu | 1 |
| Lakinina, MV | 1 |
| Stanimirovic, DB | 1 |
| Bacic, F | 1 |
| Uematsu, S | 1 |
| Spatz, M | 1 |
| Walden, J | 5 |
| Grunze, H | 2 |
| Mayer, A | 1 |
| Düsing, R | 2 |
| Schirrmacher, K | 1 |
| Liu, Z | 2 |
| Lehmenkükhler, A | 1 |
| Nicholson, C | 1 |
| Jones, D | 1 |
| Altrup, U | 1 |
| Abellán, I | 1 |
| Sempere, AP | 1 |
| Langosch, JM | 1 |
| Repp, M | 1 |
| Berger, M | 1 |
| Marinelli, S | 1 |
| Gatta, F | 1 |
| Sagratella, S | 3 |
| Owen, A | 1 |
| Pirmohamed, M | 1 |
| Tettey, JN | 1 |
| Morgan, P | 1 |
| Chadwick, D | 1 |
| Park, BK | 1 |
| Chen, Q | 1 |
| Xie, Y | 1 |
| Chai, H | 1 |
| Sasa, M | 1 |
| Ishihara, K | 1 |
| Momiyama, T | 1 |
| Renming, X | 1 |
| Todo, N | 1 |
| Amano, T | 1 |
| Serikawa, T | 1 |
| Yamada, J | 1 |
| Pohl, M | 1 |
| Popoli, P | 1 |
| Pezzola, A | 1 |
| Zeng, YC | 1 |
| Scotti de Carolis, A | 2 |
| Woodcock, BG | 1 |
| Kirsten, R | 1 |
| Nelson, K | 1 |
| Rietbrock, S | 1 |
| Hopf, R | 1 |
| Kaltenbach, M | 1 |
| Aicardi, G | 1 |
| Schwartzkroin, PA | 1 |
| Witte, OW | 1 |
| Frank, C | 1 |
| Benedetti, M | 1 |
| Marrosu, F | 1 |
| Mereu, G | 1 |
| Fratta, W | 1 |
| Carcangiu, P | 1 |
| Camarri, F | 1 |
| Gessa, GL | 1 |
3 reviews available for verapamil and Aura
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Outside the box: Medications worth considering when traditional antiepileptic drugs have failed.
Topics: Amantadine; Anticonvulsants; Bumetanide; Central Nervous System Stimulants; Epilepsy; Humans; Imipra | 2017 |
Epileptogenesis: contributions of calcium ions and antiepileptic calcium antagonists.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Cerebral Cortex; Electroencephalography; Epilep | 1992 |
2 trials available for verapamil and Aura
| Article | Year |
|---|---|
A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Calcium Channel Blockers; Combined M | 2014 |
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients.
Topics: Adult; Calcium Channel Blockers; Carbon Radioisotopes; Case-Control Studies; Chromatography, High Pr | 2008 |
39 other studies available for verapamil and Aura
| Article | Year |
|---|---|
Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy.
Topics: Amino Acid Sequence; Child; Chloride Channels; Diazepam; Electroencephalography; Epilepsy; Female; G | 2019 |
Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Ep | 2014 |
P-glycoprotein alters blood-brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2013 |
Role of P-glycoprotein in refractoriness of seizures to antiepileptic drugs in Lennox-Gastaut syndrome.
Topics: Adolescent; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channe | 2015 |
Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2014 |
L-type Calcium Channel Blockers Enhance Trafficking and Function of Epilepsy-associated α1(D219N) Subunits of GABA(A) Receptors.
Topics: Calcium Channel Blockers; Calcium Channels, L-Type; Calnexin; Calreticulin; Cell Line; Endoplasmic R | 2015 |
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Calcium | 2010 |
Add-on treatment with verapamil in pharmacoresistant canine epilepsy.
Topics: Age of Onset; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blo | 2011 |
Functional test of multidrug transporter activity in hippocampal-neocortical brain slices from epileptic patients.
Topics: Adjuvants, Pharmaceutic; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; E | 2011 |
Influences of "spasmolytic powder" on pgp expression of Coriaria Lactone-kindling drug-resistant epileptic rat model.
Topics: Animals; Anticonvulsants; Arthropods; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disea | 2013 |
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2002 |
Background potassium concentrations and epileptiform discharges. II. Involvement of calcium channels.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Epilepsy; Extracellular Space; Female; | 2003 |
Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.
Topics: Adult; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance; Dr | 2004 |
Reduction of human neocortical and guinea pig CA1-neuron A-type currents by organic calcium channel blockers.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Animals; Calcium Channel Blockers; Child; Epilepsy; Fem | 2004 |
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls | 2005 |
Organic and inorganic calcium antagonists inhibit veratridine-induced epileptiform activity in CA3 neurons of the guinea pig.
Topics: Animals; Calcium; Calcium Channel Blockers; Cobalt; Convulsants; Epilepsy; Guinea Pigs; Hippocampus; | 2008 |
Spontaneous and stimulus-triggered epileptic discharges: delayed antiepileptic effect with triggering.
Topics: Action Potentials; Animals; Dose-Response Relationship, Drug; Electric Stimulation; Epilepsy; Guinea | 1994 |
Picrotoxin-induced epileptic activity in hippocampal and neocortical slices (guinea pig): suppression by organic calcium channel blockers.
Topics: Animals; Cerebral Cortex; Depression, Chemical; Epilepsy; Female; Flunarizine; Guinea Pigs; Hippocam | 1994 |
[Anticonvulsant activity of sodium valproate and various calcium antagonists during their combined use in mice].
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Dihydropyridines; Diltiazem; Drug Therapy, Combi | 1993 |
Profile of prostaglandins induced by endothelin-1 in human brain capillary endothelium.
Topics: Analysis of Variance; Capillaries; Cell Line; Dexamethasone; Endothelin Receptor Antagonists; Endoth | 1993 |
Calcium-antagonistic effects of carbamazepine in epilepsies and affective psychoses.
Topics: Animals; Caffeine; Calcium Channel Blockers; Carbamazepine; Epilepsy; Guinea Pigs; Hippocampus; In V | 1993 |
Superfusion of verapamil on the cerebral cortex does not suppress epileptic discharges due to restricted diffusion (rats, in vivo).
Topics: Animals; Cerebral Cortex; Diffusion; Epilepsy; Perfusion; Rats; Verapamil | 1993 |
Simultaneous blockade of intracellular calcium increases and of neuronal epileptiform depolarizations by verapamil.
Topics: Animals; Calcium; Calcium Channel Blockers; Electrophysiology; Epilepsy; Helix, Snails; Intracellula | 1996 |
[The Valencia Neurological Society. A 45-year-old man with epileptic crises].
Topics: Anticonvulsants; Epilepsy; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Spain; Verapamil | 1997 |
Strychnine-induced epileptiform activity in hippocampal and neocortical slice preparations: suppression by the organic calcium antagonists verapamil and flunarizine.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Epilepsy; Evoked Pote | 1997 |
Effects of the atypical antidepressant trimipramine on field potentials in the low Mg2+-model in guinea pig hippocampal slices.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Antidepressive Agents, Tricyclic; Calcium C | 1998 |
Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity.
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Axons; Benzodiazepines; Calcium Chan | 2000 |
Differential involvement of L-type calcium channels in epileptogenesis of rat hippocampal slices during ontogenesis.
Topics: Age Factors; Animals; Animals, Newborn; Calcium Channel Blockers; Calcium Channels, L-Type; Epilepsy | 2000 |
Carbamazepine is not a substrate for P-glycoprotein.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caco-2 Cel | 2001 |
[Effects of calcium channel blocker verapamil on hippocampal kindled seizures induced by coriaria lactone in rabbits].
Topics: Animals; Electroencephalography; Epilepsy; Female; Hippocampus; Injections, Intraventricular; Kindli | 1992 |
Abnormal calcium current in hippocampal CA3 pyramidal cells of the spontaneously epileptic rat (SER).
Topics: Action Potentials; Animals; Calcium Channels; Electric Stimulation; Epilepsy; Flunarizine; Hippocamp | 1992 |
Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies.
Topics: Animals; Calcium Channel Blockers; Carbamazepine; Epilepsy; Extracellular Space; Guinea Pigs; Hippoc | 1992 |
Low magnesium-induced epileptiform discharges in guinea pig hippocampal slices: depression by the organic calcium antagonist verapamil.
Topics: Animals; Anticonvulsants; Epilepsy; Evoked Potentials; Guinea Pigs; Hippocampus; In Vitro Techniques | 1992 |
Cromakalim (BRL 34915) counteracts the epileptiform activity elicited by diltiazem and verapamil in rats.
Topics: Animals; Anticonvulsants; Benzopyrans; Cromakalim; Diltiazem; Electric Stimulation; Electroencephalo | 1991 |
A reduction in verapamil concentrations with phenytoin.
Topics: Adult; Cardiomyopathy, Hypertrophic; Drug Interactions; Epilepsy; Female; Humans; Phenytoin; Verapam | 1991 |
Suppression of epileptiform burst discharges in CA3 neurons of rat hippocampal slices by the organic calcium channel blocker, verapamil.
Topics: Action Potentials; Animals; Calcium Channels; Electric Stimulation; Epilepsy; Female; Hippocampus; I | 1990 |
Suppression of focal epileptiform discharges by intraventricular perfusion of a calcium antagonist.
Topics: Animals; Brain; Calcium Channel Blockers; Cerebral Ventricles; Electroencephalography; Epilepsy; Pen | 1985 |
Comparative influence of calcium blocker and purinergic drugs on epileptiform bursting in rat hippocampal slices.
Topics: Adenosine; Animals; Caffeine; Calcium; Epilepsy; Hippocampus; In Vitro Techniques; Magnesium; Male; | 1988 |
Different epileptogenic activities of murine and ovine corticotropin-releasing factor.
Topics: Animals; Corticotropin-Releasing Hormone; Electroencephalography; Epilepsy; Injections, Intraventric | 1987 |